Guidelines that recommend inhaled antibiotics for the treatment of chronic Pseudomonas infections in people with cystic fibrosis (CF)
| Recommendations | |
| Standards for the clinical care of children and adults with cystic fibrosis in the UK [57] | Inhaled antibiotics to be prescribed for long-term treatment of chronic Pseudomonas aeruginosa lung infections. |
| National Institute for Health and Care Excellence guidelines [58] | Eradication therapy with a course of oral or intravenous antibiotics, together with an inhaled antibiotic to be commenced for a person with CF developing a new P. aeruginosa infection. This would be followed with an extended course of oral and inhaled antibiotics. Sustained treatment with an inhaled antibiotic to be considered for people with CF who have chronic Burkholderia cepacia complex infection and declining pulmonary status, to suppress the infection. |
| European CF Society best practice guidelines, 2018 [6] | Long-term inhaled antibiotic therapy to be initiated for chronic bacterial infection with P. aeruginosa, when eradication therapy has failed. |
| Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease, 2020 [59] | A trial of continuous alternating inhaled antibiotics (as dictated by bacterial pathogens identified in respiratory culture) is recommended for people with advanced CF lung disease. |
| Cystic Fibrosis Standards of Care, Australia [60] | Children with CF require regular inhaled therapy which includes bronchodilators, inhaled steroids, antibiotics, Pulmozyme and hypertonic saline. |